Korean Market
OWNR
Icure Pharmaceutical
★

Icure Pharmaceutical Proxy Solicitation for Extraordinary General Meeting to Elect Four Directors

 
OTHR
Icure Pharmaceutical
★

Icure Pharmaceutical Calls Temporary Shareholder Meeting to Elect New Directors

 
EXCH
Icure Pharmaceutical
★

Icure Pharmaceutical Finalizes Director Candidates for EGM, No Shareholder Value Impact

 
EXCH
Icure Pharmaceutical
★

Icure Pharmaceutical Improvement Period Ends, Delisting Review Begins, Shareholder Value at Risk

 
EXCH
Icure Pharmaceutical
★

Icure Files Amendment to Taiwan License Termination Disclosure, Details TFDA Rejection Reason

 
EXCH
Icure Pharmaceutical
★

Icure Receives Termination Notice for Donepezil Patch License in Taiwan, Future Revenue Prospects Diminished

 
EXCH
Icure Pharmaceutical
★

Record Date Set for Extraordinary General Meeting, No Shareholder Value Impact

 
EXCH
Icure Pharmaceutical
★

Icure Pharmaceutical Calls Extraordinary General Meeting for Director Elections with Details to Be Decided

 
MATR
Icure Pharmaceutical
★★★

Icure Decides 54.6% Dilution Third-Party Allotment, Largest Shareholder Change and Management Improvement

 
EXCH
Icure Pharmaceutical
★

Icure Pharmaceutical's Shareholders' Meeting Petition Withdrawn by IK Partners Group, Reducing Management Dispute Risk

 
EXCH
Icure Pharmaceutical
★★

Voluntary Withdrawal of Alzheimer's Donepezil Patch US Phase 1 Trial, Avoiding 30 Billion KRW Clinical Cost

 
PERI
Icure Pharmaceutical
★

Icure Posts Operating Profit in Q1 but Faces Ongoing Delisting Risk

 
PERI
Icure Pharmaceutical
★★

ICure Q1 2026: Revenue Doubles, Operating Profit Turns Positive, Delisting Risk Remains

 
PERI
Icure Pharmaceutical
★★★

Icure: Sustained Large Net Loss and Delisting Risk - Granted Improvement Period